Imunexus
Biologics company developing multispecific therapeutic proteins by attaching engineered V-like binding modules to existing antibodies, enzymes and other protein drugs. The platform converts validated monospecific biologics into bispecific or multispecific candidates with the intent of improving efficacy, extending half-life or adding targeting functions while preserving parent protein properties and manufacturability. The company focuses on oncology, autoimmune and neurological indications and engages in partnerships with academic and industry collaborators.
Industries
Nr. of Employees
small (1-50)
Imunexus
La Trobe University, LIMS2 Building, Science Drive, Melbourne, Bundoora VIC 3086, Australia
Patents
Products
Bispecific antibody candidate for small cell lung cancer (lead candidate)
A multispecific antibody generated by fusing an engineered V-like binding module that activates immune effector cells to a small cell lung cancer‑specific parent antibody; advanced as a lead oncology program.
Bispecific enzyme candidate with half-life extension for a rare pediatric disease
An on-market enzyme replacement therapy fused to a half-life extending V-like module to reduce dosing frequency and improve administration characteristics for a rare pediatric indication.
Bispecific enzyme candidate for multiple sclerosis (research collaboration)
A bispecific enzyme program developed in collaboration with an academic research institute aiming to treat central nervous system disorders, with a primary focus on multiple sclerosis.
Bispecific antibody candidate for small cell lung cancer (lead candidate)
A multispecific antibody generated by fusing an engineered V-like binding module that activates immune effector cells to a small cell lung cancer‑specific parent antibody; advanced as a lead oncology program.
Bispecific enzyme candidate with half-life extension for a rare pediatric disease
An on-market enzyme replacement therapy fused to a half-life extending V-like module to reduce dosing frequency and improve administration characteristics for a rare pediatric indication.
Bispecific enzyme candidate for multiple sclerosis (research collaboration)
A bispecific enzyme program developed in collaboration with an academic research institute aiming to treat central nervous system disorders, with a primary focus on multiple sclerosis.
Services
Collaborative engagement offering access to a modular multispecific generation platform, including presentations and partnership discussions for biopharma companies interested in converting existing biologics into multispecific candidates.
Collaborative engagement offering access to a modular multispecific generation platform, including presentations and partnership discussions for biopharma companies interested in converting existing biologics into multispecific candidates.
Expertise Areas
- Bispecific and multispecific therapeutic development
- Monoclonal antibody engineering
- Therapeutic enzyme modification and half-life extension
- Protein scaffold engineering
Key Technologies
- Protein engineering of V-like binding domains
- High-throughput screening (HTS) of randomized libraries
- Genetic fusion/cloning into expression vectors
- Bispecific/trispecific antibody generation
News & Updates
Announcement of relocation of R&D activities to an academic molecular sciences facility.
Blog post announcing recommencement of company operations.
Blog post describing a successful capital raising event.
Published annual report for Imunexus Therapeutics Limited for the year ended 30 June 2025.
Published annual report for Imunexus Limited for the year ended 30 June 2025.
Published annual report for Imunexus Therapeutics Limited for the year ended 30 June 2024.
Announcement of relocation of R&D activities to an academic molecular sciences facility.
Blog post announcing recommencement of company operations.
Blog post describing a successful capital raising event.
Published annual report for Imunexus Therapeutics Limited for the year ended 30 June 2025.
Published annual report for Imunexus Limited for the year ended 30 June 2025.
Published annual report for Imunexus Therapeutics Limited for the year ended 30 June 2024.